Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
Tacedinaline (CI-994) 是一种 I 类 HDAC 抑制剂，可靶向 MYC 驱动的髓母细胞瘤的内在肿瘤生长和软脑膜播散，同时使其易受抗 CD47 诱导的巨噬细胞吞噬作用的影响，该作用通过 NF-kB-TGM2 驱动的肿瘤炎症实现
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.3
doi:10.1136/jitc-2022-005871
Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Nan Qin, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Allison Cole, Joselyn Cruz-Cruz, Claus M Graef, Matthias Wölfl, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf K
